Trypanosoma cruzi Infection and Endothelin-1 Cooperatively Activate Pathogenic Inflammatory Pathways in Cardiomyocytes
Author(s) -
Ricardo S. Corral,
Néstor Guerrero,
Henar Cuervo,
Núria Gironès,
Manuel Fresno
Publication year - 2013
Publication title -
plos neglected tropical diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.99
H-Index - 135
eISSN - 1935-2735
pISSN - 1935-2727
DOI - 10.1371/journal.pntd.0002034
Subject(s) - nfat , atrial natriuretic peptide , calcineurin , trypanosoma cruzi , chagas disease , endothelin 1 , endothelins , pathogenesis , immunology , biology , eicosanoid , eicosanoid metabolism , cardiomyopathy , medicine , heart failure , endocrinology , transplantation , receptor , parasite hosting , biochemistry , world wide web , computer science , arachidonic acid , enzyme
Trypanosoma cruzi , the causative agent of Chagas' disease, induces multiple responses in the heart, a critical organ of infection and pathology in the host. Among diverse factors, eicosanoids and the vasoactive peptide endothelin-1 (ET-1) have been implicated in the pathogenesis of chronic chagasic cardiomyopathy. In the present study, we found that T. cruzi infection in mice induces myocardial gene expression of cyclooxygenase-2 ( Cox2 ) and thromboxane synthase ( Tbxas1 ) as well as endothelin-1 ( Edn1 ) and atrial natriuretic peptide ( Nppa ). T. cruzi infection and ET-1 cooperatively activated the Ca 2+ /calcineurin (Cn)/nuclear factor of activated T cells (NFAT) signaling pathway in atrial myocytes, leading to COX-2 protein expression and increased eicosanoid (prostaglandins E 2 and F 2α , thromboxane A 2 ) release. Moreover, T. cruzi infection of ET-1-stimulated cardiomyocytes resulted in significantly enhanced production of atrial natriuretic peptide (ANP), a prognostic marker for impairment in cardiac function of chagasic patients. Our findings support an important role for the Ca 2+ /Cn/NFAT cascade in T. cruzi -mediated myocardial production of inflammatory mediators and may help define novel therapeutic targets.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom